Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05649956 · ClinicalTrials.gov registry record · Phase 2

Letrozole in Uterine Leiomyosarcoma

A Phase 2 study of Uterine Leiomyosarcoma, sponsored by GOG Foundation.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
13
Study locations

NCT05649956 is a Phase 2 study of Uterine Leiomyosarcoma that is actively recruiting participants, run by GOG Foundation. The registered enrollment target is 40 participants, above the 36-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (11% higher). The trial reports 13 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05649956, a Phase 2 study of Uterine Leiomyosarcoma, is actively recruiting participants, sponsored by GOG Foundation.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
13
Study locations

Study Summary

This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.

Conditions Studied

Uterine Leiomyosarcoma

Interventions

  • DRUG Letrozole

Study Locations (13)

Colorado

  • University of Colorado Cancer Center - Anschutz Cancer Pavilion - Aurora
  • Highlands Ranch Hospital - Highlands Ranch

Nevada

  • Women's Cancer Center of Nevada - Las Vegas
  • Women's Cancer Center of Nevada - Las Vegas

Florida

  • Mount Sinai Comprehensive Cancer Center - Miami Beach

Illinois

  • Endeavor Health - Kellogg Cancer Center - Evanston

Louisiana

  • WK Physician Network-Gynecologic Oncology Associates - Shreveport

Massachusetts

  • University of Massachusetts Memorial Medical Center - Worcester

New Mexico

  • University of New Mexico Comprehensive Cancer Center - Albuquerque

North Carolina

  • East Carolina University Health Medical Center - Greenville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-07-17
Est. Completion 2029-07-30
Phase Phase 2

Sponsor

GOG Foundation

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05649956

The ClinicalTrials.gov registry entry for NCT05649956 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 36-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (11% higher). The listed sponsor is GOG Foundation, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Uterine Leiomyosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Letrozole is the first listed.

NCT05649956 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Colorado, Nevada, Florida.

Frequently Asked Questions

What is clinical trial NCT05649956 about?

NCT05649956 is a clinical study titled "Letrozole in Uterine Leiomyosarcoma". This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.

What is the current status of trial NCT05649956?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-07-17. Estimated completion is 2029-07-30.

What conditions does trial NCT05649956 study?

This clinical trial studies the following conditions: Uterine Leiomyosarcoma.

What interventions are being tested in trial NCT05649956?

The interventions under investigation include: Letrozole (DRUG).

Who is sponsoring clinical trial NCT05649956?

This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05649956 being conducted?

This trial has 13 study locations across Colorado, Florida, Illinois, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uterine Leiomyosarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Uterine Leiomyosarcoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.